Quanterix Corporation is a life sciences company that provides ultra-sensitive translational research and spatial biology instruments, consumables, and services to accelerate biomarker breakthroughs from discovery to diagnostics. The company's proprietary Simoa technology enables the detection of protein biomarkers at ultra-low concentrations in blood, serum, and other fluids, while its Spatial Biology platforms allow for multi-plexing biomarker analysis in tissue samples at single-cell resolution. Quanterix sells its instruments and related consumables worldwide to research laboratories, contract research organizations, academic institutions, and biopharmaceutical companies. It also offers contract research services and clinical laboratory testing through its CLIA-certified Accelerator Laboratory, which includes Laboratory Developed Tests such as the LucentAD Complete multiplex test for Alzheimer’s disease. The company acquired Akoya Biosciences in 2025 to expand its spatial phenotyping capabilities and Emission, Inc. in 2025 to secure supply of magnetic beads for next-generation platforms. Quanterix serves customers in North America and Europe directly and globally through distributor partners, with applications in neurology, oncology, immunology, and inflammation research.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Diagnostics & Research Homepage quanterix.com
Sector Healthcare IR page quanterix.com
Tags
biomarker detection, spatial biology, ultrasensitive immunoassay, protein analysis, clinical diagnostics, tissue phenotyping, laboratory developed tests, neurology diagnostics, oncology research, immunology research, Simoa, Accelerator Laboratory, LucentAD Complete, Akoya Biosciences, Emission, PhenoImager HT 2.0, PhenoCode Molecular Barcoding Kit, Quanterix Spatial Accelerator, phenoptr, phenoptrReports
Press page quanterix.com/news-media-center/press-releases

Metrics

Valuation  
Market cap $ 176.043M
Market cap (USD) $ 176.043M
P/E -1.58
PEG —
P/BV 0.80
P/S 1.19
P/OCF -3.15
P/FCF -3.14
Dividend yield —
Turnover / mcap —
Returns  
ROE -34.2%
ROI -36.3%
ROIC -31.9%
Profit margin -77.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 40
Quality score -47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 138.897M 137.421M 122.368M 105.522M 110.556M 86.377M 56.734M 37.632M 22.874M
Net profit -107.15M -38.531M -32.334M -96.7M -57.688M -31.53M -40.796M -31.536M -27.019M
Free cash flow -79.848M -38.532M -22.69M -59.998M -61.523M -27.295M -37.034M -30.239M -23.238M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 6.36 10.63 27.34 13.85 42.4 46.5 23.63 18.31 21.47
Price performance 12m -0.4 -0.61 0.97 -0.67 -0.09 0.97 0.29 -0.15 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 5.6M 6.79M 10.9M 17.2M 23.8M 19M 25.4M 32.1M 30M
↳ YoY growth +21.3% +60.6% +57.6% +38.4% -20.0% +33.6% +26.5% -6.7%
↳ 5y CAGR +27.7% +30.2% +24.1% +11.8%
Borrowings, current (USD) 899,000 5.04M — 75,000 7.67M — — — — —
Borrowings, non-current (USD) 9.34M 4.35M 7.62M 7.59M — — — — — —
Lease liabilities (USD) — — — — 23.1M 21.9M 44.1M 41.5M 37.4M 37.2M
Cash and deposits (USD) 29.7M 79.7M 44.4M 109M 182M 396M 339M 174M 56.7M 29.8M
Intangible assets (USD) — — 2.35M 14.3M 13.7M 10.5M 7.52M 6.03M 4.03M 132M
Right-of-use assets (USD) — — — — 12M 11.5M 21.2M 18.3M 16.3M 16.7M
Net debt (borrowings + leases - cash) (USD) -19.4M -70.3M -36.8M -102M -151M — — — — —
Cash flow detail
Operating cash flow (USD) -17.7M -22.1M -28.7M -26.2M -23.4M -47.9M -48.3M -18.9M -35.2M -77.2M
Purchases of property, plant and equipment (USD) 526,000 1.13M -1.52M -10.8M -3.93M -13.6M -11.7M -3.79M -3.37M -2.61M
Change in receivables (cash effect) (USD) 1.66M 1.68M -983,000 -3.37M -6.24M -6.85M 5.16M -6.7M -7.7M 10.6M
Change in inventories (cash effect) (USD) 526,000 2.04M -1.6M -3.45M -5.12M -8.09M 5.39M -5.36M -6.68M 4.03M
Change in payables (cash effect) (USD) 1.13M 1M — — — — — — — —
Interest paid (cash effect) (USD) -945,000 -743,000 -660,000 -656,000 -625,000 -389,000 — — — —
Income taxes paid (cash effect) (USD) — — — — — — -684,000 -808,000 -875,000 -1.4M
Share-based compensation (USD) 928,000 2.17M 4.88M 6.39M 10.1M 16M 15.4M 16.8M 20M 20.7M
Operating cash flow before change in receivables (USD) -19.4M -23.8M -27.7M -22.8M -17.1M -41.1M -53.4M -12.2M -27.5M -87.8M
Free cash flow (OCF - PPE - intangibles) (USD) -18.3M -23.2M -30.2M -37M -27.3M -61.5M -60M -22.7M -38.5M -79.8M
Income detail
Research and development expense (USD) 17M 16.3M 15.8M 16.2M 20.2M 28M 25.9M 24.9M 31.1M 35.9M
↳ 5y CAGR +14.9% +10.5% +9.7% +9.5% +13.9% +12.2%
Total comprehensive income (USD) — -27M -31.5M -40.9M -28.9M -59.7M -99.8M -31.5M -39.9M -105M
Comprehensive income to owners (USD) — -27M -31.5M -40.9M -28.9M -59.7M -99.8M -31.5M -39.9M -105M
Provision for credit losses (USD) — — — 160,000 493,000 213,000 -301,000 336,000 588,000 628,000
Credit cost ratio (credit losses / average receivables) (%) — — — 1.8% 3.5% 1.0% 1.4% 1.5% 2.0% 2.0%
Reported Mar 19, 2018 Mar 13, 2020 Mar 13, 2020 Mar 1, 2022 Mar 1, 2022 Mar 1, 2022 Mar 6, 2023 Feb 29, 2024 Mar 17, 2025 Mar 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Quanterix Announces Leadership Transition Plan Bull 0 Bear 3 Management

Everett Cunningham Steps Down as President and CEO to Accept Another Opportunity

Jim Gute, Quanterix’s Chief Commercial Officer, Appointed to the Additional Role of Interim President and CEO

Board Has Initiated a Search for a New CEO

Company Reaffirms 2026 Business Outlook

BILLERICA, Mass., November 18, 2026 – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that Everett Cunningham has stepped down as President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”), effective immediately, to accept an opportunity in another area of the healthcare sector.

The Board has appointed Jim Gute, Quanterix’s Chief Commercial Officer, to serve in the additional role of Interim President and CEO while it conducts a search for a new CEO. The Board has engaged a nationally recognized executive search firm to assist with this process and will consider both internal and external candidates. Mr. Cunningham will remain available to assist with an orderly transition of his responsibilities through December 11, 2026.

Reports $35.0 million in revenue, up 6.3% sequentially, and $80.7 million of cash and marketable securities

Initiatives to accelerate commercial effectiveness position the Company for growth in rest of 2026 and going forward

BILLERICA, Mass. – November 9, 2026 -- Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the third quarter ended September 30, 2026.

“We delivered higher than expected topline growth in the third quarter, with revenues up 6.3% sequentially, despite continued market softness. This first step in restoring growth reflects sequential improvement across all our businesses. The actions we initiated last quarter to improve commercial performance, including reorganizing our teams and adding experienced leadership and discipline, should accelerate our execution in the fourth quarter and beyond,” said Everett Cunningham, President & CEO of Quanterix.

He added, “We are confident about the benefits and differentiated positioning of our research tools and diagnostics businesses, especially with new commercial leadership focused on sustained growth.

Oct 28, 2026

PDF Version

BILLERICA, Mass.--(BUSINESS WIRE)--Oct. 28, 2026-- Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, November 9, 2026, at 8:30 AM ET, to discuss its third quarter 2026 financial results.

Quanterix will issue a press release regarding its third quarter 2026 financial results prior to the conference call on Monday, November 9, 2026. The press release will be posted on the Quanterix website at http://www.quanterix.com/.

In conjunction with this announcement, the Company will host a conference call on November 9, 2026, at 8:30 AM ET. The dial-in number for USA & Canada is Toll-Free (800) 715-9871 or (646) 307-1963 and the conference ID is 3290884.

Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at https://ir.quanterix.com. An archived webcast replay will be available on the Company’s website for one year.

About Quanterix

Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics. Learn more at www.quanterix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261028850946/en/

Media [email protected]

Investor Relations [email protected]

Source: Quanterix Corporation

Print Page

Print Page

Email Alerts

Email Alerts

RSS

RSS

IR Contacts

IR Contacts

Prompts

Quanterix Corporation (ticker QTRX), listed in United States.

ETFs Holding Quanterix Corporation

ETF Weight in ETF Shares Market value As of
FESM 0.01% 200,221 $ 864.955K Jun 30, 2026
AVSC 0.01% 89,547 $ 254.313K Nov 16, 2026
DFSU 0.00% 5,272 $ 15.078K Nov 12, 2026
DXUV 0.00% 358 $ 1,023.88 Nov 12, 2026
AVUS 0.00% 7,397 $ 21.007K Nov 16, 2026